Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - October 2013


SMi - Orphan Drugs & Rare Diseases

14 Oct 2013 - 15 Oct 2013 - London, UK



Bookmark and Share


Recent years have seen huge growth in orphan drug development, but also a time of increased pressure as many leading blockbuster drugs soon come off patent.

Join SMi for their 2nd Annual Orphan Drugs & Rare Diseases conference as they showcase world leading experts speaking inclusively on the orphan drug industry featuring cutting edge research via case studies taking place in previously untreatable patients. The conference will highlight current regulatory policies involving the FDA & EMA, new drug discoveries and partnerships in clinical trials and drug development with patient groups.

There will also be a 'big pharma spotlight session' highlighting where current pipelines stand and where the next blockbuster will be treating rare diseases, including discussions on HTA and pricing issues currently being implemented after recent reforms in Europe.

KEY REASONS TO ATTEND

Review through a unique 'Big Pharma Spotlight' session what drugs are finishing late stage clinical trials and where pipelines currently lead

Discover how market access and HTA are affecting Orphan Drug releases

Review optimal targeting for your new drug with expert analysis in patient selection and recruitment

Learn from case studies of new molecules in clinical trials

Analyse current funding options; including financial and economic reimbursement for the clinical development of drugs

Register online here: www.smi-online.co.uk/2013orphandrugs13.asp

Alternatively, contact: Jonathan Collins on +44 (0)20 7827 6734 or email: jcollins@smi-online.co.uk 

Academic & Group discounts available




Further information
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Identified Compound Stops Cells Making Ribosomes
From study in yeast, researchers have identifed a compound that interferes with the assembly of ribosomes.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!